Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

  • Gemma Bruera1, 2,
  • Katia Cannita1,
  • Daniela Di Giacomo2,
  • Aude Lamy3,
  • Thierry Frébourg4,
  • Jean Christophe Sabourin5,
  • Mario Tosi4,
  • Edoardo Alesse2,
  • Corrado Ficorella1, 2 and
  • Enrico Ricevuto1, 2Email author
BMC Medicine201311:59

DOI: 10.1186/1741-7015-11-59

Received: 29 September 2012

Accepted: 4 March 2013

Published: 4 March 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
29 Sep 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
29 Sep 2012 Author responded Author comments - Enrico Ricevuto
Resubmission - Version 3
29 Sep 2012 Submitted Manuscript version 3
5 Nov 2012 Reviewed Reviewer Report - raffaele palmirotta
10 Nov 2012 Reviewed Reviewer Report - Takayuki Yoshino
5 Dec 2012 Reviewed Reviewer Report - Paolo Correale
14 Dec 2012 Author responded Author comments - Enrico Ricevuto
Resubmission - Version 4
14 Dec 2012 Submitted Manuscript version 4
12 Jan 2013 Author responded Author comments - Enrico Ricevuto
Resubmission - Version 5
12 Jan 2013 Submitted Manuscript version 5
Publishing
4 Mar 2013 Editorially accepted
4 Mar 2013 Article published 10.1186/1741-7015-11-59

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Medical Oncology, S. Salvatore Hospital, University of L'Aquila
(2)
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila
(3)
Laboratory of Tumor Genetics, University Hospital
(4)
INSERM U614, University of Rouen
(5)
Department of Pathology, INSERM U614, Rouen University Hospital

Advertisement